{
    "@graph": [
        {
            "@id": "gnd:1222926067",
            "sameAs": "Schade, Nico"
        },
        {
            "@id": "gnd:2024276-1",
            "sameAs": "Martin-Luther-Universit\u00e4t Halle-Wittenberg"
        },
        {
            "@id": "https://www.tib.eu/de/suchen/id/TIBKAT%3A1742199712",
            "@type": "bibo:Thesis",
            "P1053": "1 Online-Ressource (270 Seiten)",
            "description": "Illustrationen, Diagramme",
            "identifier": [
                "(firstid)KXP:1742199712",
                "(doi)10.25673/35193",
                "(ppn)1742199712"
            ],
            "title": "Entwicklung neuer multitargeting Kinaseinhibitoren zur Bek\u00e4mpfung der Alzheimerschen Erkrankung",
            "abstract": [
                "The brain of Alzheimer Disease (AD) patients is characterized by A\u03b2 proteins and neurofibrillary tangles (NFTs). The agglomeration of NFTs correlates with increased concentration of protein kinases. Azoxafluorenes can be inhibited this kinases and could be therapeutic solution for AD. So 52 new azoxafluorenes with carbamide or oxime ether residues are synthesized. On basis of two steps synthesis by VOIGT, the synthesized pyridinecarbamides and nicotinaldehyde oxime ethers were converted in 3,4-disubstituted N-acetyl-1,4-dihydropyridines by acetyl chloride, copper one iodide, lithium chloride and phenylmagnesium chloride. These intermediate compounds reacted with several quinones in a five percentage perchloric acid solution to give tricyclic and tetracyclic azoxafluorenes. The new compounds were tested on CDK1, CDK2, ERK1, JNK3, GSK3\u03b2 and Fyn wt. The Compounds 23, 28, 33, 77, 88 showed activities with IC50 values of one to 40 \u03bcM. Dockings experiments of selected compounds showed hydrogen bonds and hydrophobic interactions with the target kinases JNK3 and Fyn.",
                "Neurofibrill\u00e4re Verwicklungen (NFT), Proteinkinasen, Alzheimer (AD), Dihydropyridine, Azoxafluorene, Nicotinamide, Nicotincarbaldehydoximether, Anisotropie, E/Z-Isomerie",
                "neurofibrillary Tangles (NFT), proteine kinases, Alzheimer Diseases (AD), dihydropyridine, azoxafluorenes, nicotinamides, nicotincarbaldehyde oxime ethers, anisotropic effect, E/Z-isomeric effect",
                "Das Gehirn von Alzheimerpatienten ist charakterisiert durch A\u03b2-Proteine und Neurofibrill\u00e4re Verwicklungen (NFTs). Die Agglomeration der NFTs korreliert mit einer erh\u00f6hten Konzentration an Proteinkinasen. Azoxafluorene k\u00f6nnen diese inhibieren und k\u00f6nnten somit eine therapeutische L\u00f6sung f\u00fcr AD darstellen. 52 neue Azoxafluorene mit Carbamid oder Oximether Seitenkette konnten synthetisiert werden. Auf Basis von VOIGTs Zweitschrittsynthese wurden die synthetisierten Nicotinamide und Nicotincarbaldehydoximether in 3,4-disubstituierte N-Acetyl-1,4-dihydropyridine mit Hilfe von Acetylchlorid, Kupfer-I-jodid, Lithiumchlorid und Phenylmagnesiumchlorid umgewandelt. Diese Verbindungen reagierten anschlie\u00dfend mit verschiedenen Chinonen in einer f\u00fcnfprozentigen Perchlors\u00e4urel\u00f6sung zu tri- und tetrazyklischen Azoxafluorenen. Die neuen Verbindungen wurden an der CDK1, CDK2, ERK1, JNK3, GSK3\u03b2 und Fyn wt getestet. Verbindung 23, 28, 33, 77, 88 zeigte dabei IC50 Werte von ein bis 40 \u03bcM. Docking Experimente von ausgew\u00e4hlten Verbindungen zeigten Wasserstoffbr\u00fccken und hydrophobe Wechselwirkungen mit den Zielstrukturen JNK3 und Fyn."
            ],
            "contributor": [
                "Technische Informationsbibliothek (TIB)",
                {
                    "@id": "gnd:118050060"
                },
                {
                    "@id": "gnd:12201622X"
                },
                {
                    "@id": "gnd:130241636"
                }
            ],
            "creator": [
                "gnd:1222926067",
                "gnd:2024276-1"
            ],
            "isPartOf": "(collectioncode)GBV-ODiss",
            "issued": "2020",
            "language": "http://id.loc.gov/vocabulary/iso639-1/de",
            "license": "open access",
            "medium": "rda:termList/RDACarrierType/1018",
            "isLike": "doi:10.25673/35193",
            "P60163": "Halle"
        }
    ],
    "@id": "urn:x-arq:DefaultGraphNode",
    "@context": {
        "sameAs": "http://www.w3.org/2002/07/owl#sameAs",
        "subject": "http://purl.org/dc/elements/1.1/subject",
        "identifier": "http://purl.org/dc/elements/1.1/identifier",
        "abstract": "http://purl.org/dc/terms/abstract",
        "P1053": "http://iflastandards.info/ns/isbd/elements/P1053",
        "issued": "http://purl.org/dc/terms/issued",
        "language": {
            "@id": "http://purl.org/dc/terms/language",
            "@type": "@id"
        },
        "contributor": "http://purl.org/dc/terms/contributor",
        "title": "http://purl.org/dc/elements/1.1/title",
        "isPartOf": "http://purl.org/dc/terms/isPartOf",
        "P60163": "http://www.rdaregistry.info/Elements/u/#P60163",
        "description": "http://purl.org/dc/elements/1.1/description",
        "isLike": {
            "@id": "http://umbel.org/umbel#isLike",
            "@type": "@id"
        },
        "creator": {
            "@id": "http://purl.org/dc/terms/creator",
            "@type": "@id"
        },
        "medium": {
            "@id": "http://purl.org/dc/terms/medium",
            "@type": "@id"
        },
        "license": "http://purl.org/dc/terms/license",
        "umbel": "http://umbel.org/umbel#",
        "rdau": "http://www.rdaregistry.info/Elements/u/#",
        "owl": "http://www.w3.org/2002/07/owl#",
        "dcterms": "http://purl.org/dc/terms/",
        "bibo": "http://purl.org/ontology/bibo/",
        "rdam": "http://www.rdaregistry.info/Elements/m/#",
        "gnd": "http://d-nb.info/gnd/",
        "isbd": "http://iflastandards.info/ns/isbd/elements/",
        "rda": "http://rdvocab.info/",
        "doi": "https://doi.org/"
    }
}